Jagsonpal Pharmaceuticals Ltd. · NSE:JAGSNPHARM
Jagsonpal Pharmaceuticals — FY2023 Earnings Presentation
14 slides from Jagsonpal Pharmaceuticals's earnings presentation, May 23, 2023
Slide 1: Jagsonpal Pharmaceuticals Limited FY23 Earnings Presentation
Jagsonpal Pharmaceuticals Limited FY23 Earnings Presentation May 23, 2023
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 3: FY23 Performance
JAGSONPAL FY23 Performance
Slide 4: Management Commentary
Management Commentary FY23 has been an extremely important and transformational year for us at Jagsonpal. The year saw Infinity Holdings becoming the largest shareholder in the company and the consequent changes across the governance and operational framework. I am pleased to report strong performan
Slide 5: Earnings Summary
Earnings Summary All values in ₹ lakhs Performance Revenue Op. EBITDA* Profit Before Tax Profit After Tax Q4FY23 5,545 936 732 560 YoY Growth 8.2% 12x 16x 18x FY23 23,671 4,337 3,481 2,672 YoY Growth 8.8% 73.3% 30.7% 41.8% 5 * Before ESOP accounting and one-time expenses
Slide 6: FY23 – Foundation strengthened for stronger future
FY23 – Foundation strengthened for stronger future Onboarded Infinity Holdings as joint promoter – Induction of new Board for strategic direction Controls and Governance - Big-5 as auditor, Internal auditor, Risk control frame-work Realigned leadership, organization structure, ESOPs rolled out for l
Slide 7: Key Drivers
Key Drivers Business Updates o Continuing outperformance of domestic pharmaceutical industry (Source: IQVIA) on a full year basis o Overall growth of 10.5% vis-à-vis industry growth of 7.9% o Strong performance by Dydrogesterone franchise – collectively 3.8%+ market share; Ranked 7th in industry o M
Slide 8: Key Brands Progression
Key Brands Progression All values in ₹ crores JPL Sales Market size Molecule Brand FY22 FY23 Gr % FY22 FY23 Gr % Hydroxyprogesterone Maintane Inj. 32.5 40.0 23.3% 131.6 155.7 18.3% Indomethacin Indocap SR 32.3 38.7 19.9% 45.5 52.2 14.7% Divatrone/ Dydrogesterone* 13.3 38.1 185.6% 606 1,001 65.2% Pro
Slide 9: Financial Performance
JAGSONPAL Financial Performance
Slide 10: Profit and Loss Statement
Profit and Loss Statement All values in ₹ lakhs Q4 FY 23 Q3 FY 23 Q4 FY 22 FY 23 FY 22 Particulars Audited Unaudited Audited Audited Audited Revenue From Operations 5,545 6,014 5,123 23,671 21,758 Material Consumption -2,251 -2,314 -2,339 -9,310 -8,896 Gross Margin 3,294 3,700 2,784 14,361 12,862 %
Slide 11: Key Balance Sheet Items
Key Balance Sheet Items All values in ₹ lakhs Particulars March 31, 2023 March 31, 2022 Shareholders Funds 15,889 13,276 Tangible Assets 1,835 2,257 Financial Assets (Cash & 11,689 2,545 Equivalents) Net Working Capital 2,312 3,505 11
Slide 12: Improving Financial Matrices
Improving Financial Matrices All values in ₹ Crores CAGR: 9.1% CAGR: 47% 12
Slide 13: Improving Financial Matrices
Improving Financial Matrices All values in ₹ Crores 13 *Net of Treasury Investments
Slide 14: Thank You
JAGSONPAL Thank You
Jagsonpal Pharmaceuticals — FY2023 Earnings Presentation on 6ix